featured
Discontinuing Infliximab in Patients With Ulcerative Colitis in Remission
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Discontinuation of Infliximab in Patients With Ulcerative Colitis in Remission (HAYABUSA): A Multicentre, Open-Label, Randomised Controlled Trial
Lancet Gastroenterol Hepatol 2021 Apr 19;[EPub Ahead of Print], T Kobayashi, S Motoya, S Nakamura, T Yamamoto, M Nagahori, S Tanaka, T Hisamatsu, F Hirai, H Nakase, K Watanabe, T Matsumoto, M Tanaka, T Abe, Y Suzuki, M Watanabe, T HibiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.